

A large, stylized orange grid pattern resembling a globe or a network, covering the entire background of the slide.

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024


Fact sheet for CML

For more information, visit: www.touchONCOLOGY.com

What are the latest data for approved and emerging TKIs for CML in the first-line setting?

ASC4FIRST study of asciminib vs all SoC TKIs in newly diagnosed CML¹

Patients with MMR at 48 weeks (%)




Safety and tolerability

AEs, %	Asciminib (n=200)	2G-TKIs (n=102)	Imatinib (n=99)
Grade ≥3	38	55	44
Leading to discontinuation	5	10	11
Leading to dose adjustment/interruption	30	53	39

Asciminib demonstrated superior efficacy vs 2G-TKIs and imatinib in newly diagnosed CML, with acceptable safety and tolerability

ALERTCML study of asciminib in newly diagnosed CML-CP^{2,3}

Patients achieving an MR[‡] (%; N=36)
Median follow-up: 24 weeks²




Grade 3 non-haematological toxicities³

	No. of patients
Elevated CPK	1
Increased lipase	2

Asciminib is effective and well tolerated in the first-line setting

Study of ponatinib in newly diagnosed CML-CP⁴

Patients achieving CCyR and MMR (%; N=51)
Median time on therapy: 13 months



Safety and tolerability	%
CV SAEs	16
Dose reduction due to CV AEs	16
Permanent discontinuation due to CV AEs	10

Ponatinib was associated with high CCyR and MR rates in newly diagnosed CML-CP but CV toxicity posed a challenge for its first-line use


*Estimated using the Mantel-Haenszel method after stratifying for prerandomization-selected TKI and baseline ELTS risk groups (both IRT data). Adjusted 1-sided p-value calculated based on the graphical gatekeeping procedure. †Imatinib (n=102) + 2G-TKI (n=102; nilotinib, 48%; dasatinib, 41%; and bosutinib, 11%). ‡MR2, BCR::ABL ≤1%; MR3, BCR::ABL ≤0.1%; MR4, BCR::ABL ≤0.01%; MR5, BCR::ABL ≤0.001%.

What are the latest data for approved and emerging TKIs for CML in the second- and later-line settings?

BOGI trial of lower initiating bosutinib dose in second/third-line CML-CP⁵

Patients discontinuing bosutinib at 12 months (%)

- This study: 200 mg starting dose (n=35)⁵
- Previous study: 500 mg starting dose (n=28)⁶




Cumulative incidence of response at 12 months
 MMR: 23 (66%)
 DMR: 15 (43%)

The lower initiating bosutinib dose reduced the drug discontinuation rate due to severe DRTs, while maintaining clinical efficacy

DasaHIT trial of dasatinib tolerability with weekend holidays vs 7-day dosing⁷

Patients achieving MMR at 24 months (%)

- Experimental arm: 100 mg QD, 5 + 2 days' rest
- Standard arm: 100 mg QD, 7 days



Safety and tolerability

	Exp. arm	Stand. arm
Median cTS, n	2	2
Pleural and pericardial effusions, %	8	16

Dose modification of dasatinib improved safety. While efficacy was maintained in the first line; later-line patients benefitted more from continuous dosing


OPTIC trial of ponatinib in patients with CML-CP and the T315I mutation⁸

Efficacy in patients with the T315I mutation (%; N=67)⁹

Median follow-up 60.6–63.5 months⁸

Starting dose

- 15 mg (n=21)
- 30 mg (n=21)
- 45 mg (n=25)



Safety and tolerability⁸

AEs, %	15 mg (n=21)	30 mg (n=21)	45 mg (n=25)
Grade ≥3 TEAE	38	38	60
TEAEs leading to discontinuation	5	14	8
TE-AOE	5	14	8


The optimal ponatinib benefit:risk ratio was achieved with a starting dose of 45 mg QD, reducing to 15 mg QD on attaining ≤1% BCR::ABL1S

What are the emerging findings from clinical trials and real-world studies?

First-in-human trial of asciminib in T315I-mutated CML-CP: Final analysis¹⁰

Cumulative MMR over time with asciminib 200 mg BID (n=45)
 Median exposure, 3.5 years

- Ponatinib-naïve (n=19)
- All evaluable (n=45)
- Prior ponatinib (n=26)




AEs, %	All patients (N=48)
Leading to dose adj./interrupt.	44
Leading to discontinuation	10

Asciminib is a treatment option for T315I-mutated CML-CP; it potentially provides sustained efficacy and tolerability, regardless of prior ponatinib treatment

SWOG S1712: Efficacy of ruxolitinib plus BCR::ABL1 TKIs in CML¹¹

Patients with MR at 12 months (%)
 Median time on TKI prior to enrolment: 3.2 years

- Arm A (single-agent TKI, n=38)
- Arm B (ruxolitinib + current TKI, n=37)



Proportion of patients who met NCCN criteria to discontinue TKI therapy: 29% (Arm B) vs 11% (Arm A), p=0.08


Safety	Arm A	Arm B
Grade 3 AEs, n	2	3

The ruxolitinib plus TKI combination warrants further investigation to determine if it could lead to higher TFR rates

INFINITY Czech CML database: Real-world efficacy of first-line nilotinib vs imatinib¹²

TKI efficacy (%)

- Nilotinib (n=163)
- Imatinib [matched] (n=163)



No difference in disease-specific survival between matched groups or all four groups,† due to older age and comorbidities in the imatinib-unmatched groups

First-line nilotinib demonstrated higher FFS and EFS but did not show any benefit for OS. Imatinib is still an effective choice for first-line treatment of CML-CP

*MR4.0, BCR::ABL ≤0.01%; MR4.5, BCR::ABL ≤0.0032%. †The four groups: imatinib (all, n=821); nilotinib (n=163); imatinib matched (n=163); imatinib unmatched (n=658).

Abbreviations and references

Abbreviations

2G, second generation; AE, adverse event; adj., adjustment; ASC, asciminib; BCR::ABL1IS, BCR::ABL1 International Scale; BID, twice daily; CCyR, complete cytogenetic response; CML, chronic myeloid leukaemia; CML-CP, CML-chronic phase; CPK, creatine phosphokinase; cTS, cumulative toxicity score; CV, cardiovascular; DMR, deep molecular response; DRT, drug-related toxicity; EFS, event-free survival; EHA, European Hematology Association; ELTS, European Treatment and Outcome Study long-term survival score; ESH, European School of Haematology; Exp., experimental; FFS, failure-free survival; G, generation; iCMLf, International Chronic Myeloid Leukaemia Foundation; IMA, imatinib; interrupt., interruption; IRT, interactive response technology; IS, investigator-selected; MMR, major molecular response; MR, molecular response; NCCN, National Comprehensive Cancer Network; OS, overall survival; PFS, progression-free survival; QD, once daily; SAE, serious AE; SoC, standard of care; Stand., standard; TE-AOE, TE arterial occlusive event; TEAE, treatment-emergent AE; TFR, treatment-free remission; TKI, tyrosine kinase inhibitor.

References

1. Hochhaus A, et al. Presented at: EHA 2024 Hybrid Congress, Madrid, Spain. 13–16 June 2024. Oral presentation S103.
2. Atallah E, et al. *HemaSphere*. 2024;8(S1):1268–9.
3. Atallah E, et al. Presented at: EHA 2024 Hybrid Congress, Madrid, Spain. 13–16 June 2024. Poster presentation P730.
4. Haddad F, et al. *HemaSphere*. 2024;8(S1):1245–6.
5. Kimura S, et al. *HemaSphere*. 2024;8(S1):1247–8.
6. Nakaseko C, et al. *Int J Hematol*. 2015;101:154–64.
7. La Rosée P, et al. *HemaSphere*. 2024;8(S1):154–5.
8. Apperley J, et al. *HemaSphere*. 2024;8(S1):156–8.
9. Deininger M, et al. *J Clin Oncol*. 2024;42(Suppl. 16):6501.
10. Cortes J, et al. Presented at: ESH-iCMLf 2024, Prague, Czech Republic, 27–29 September. Oral presentation.
11. Sweet K, et al. *HemaSphere*. 2024;8(S1):159–60.
12. Belohlavkova P, et al. *HemaSphere*. 2024;8(S1):1251–4.

The guidance provided by this fact sheet is not intended to directly influence patient care. Clinicians should always evaluate their patients' conditions and potential contraindications and review any relevant manufacturer product information or recommendations of other authorities prior to consideration of procedures, medications or other courses of diagnosis or therapy included here.

Our fact sheet coverage does not constitute implied endorsement of any product(s) or use(s). touchONCOLOGY cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions.